Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study

Andreas G. Wibmer; Michael J. Morris; Mithat Gonen; Junting Zheng; Hedvig Hricak; Steven Larson; Howard I. Scher; Hebert Alberto Vargas

doi:10.2967/jnumed.120.256602

Research ArticleClinical Investigation

Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study

Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven Larson, Howard I. Scher and Hebert Alberto Vargas

Journal of Nuclear Medicine August 2021, 62 (8) 1050-1056; DOI: https://doi.org/10.2967/jnumed.120.256602

Andreas G. Wibmer

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael J. Morris

2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mithat Gonen

3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Junting Zheng

3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hedvig Hricak

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Steven Larson

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Howard I. Scher

2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hebert Alberto Vargas

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 62 no. 8 1050-1056

DOI

https://doi.org/10.2967/jnumed.120.256602

PubMed

33419944

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication September 10, 2020
Accepted for publication December 14, 2020
Published online July 30, 2021.

Article Versions

previous version (January 8, 2021 - 13:20).
You are viewing the most recent version of this article.

Author Information

Andreas G. Wibmer¹,
Michael J. Morris²,
Mithat Gonen³,
Junting Zheng³,
Hedvig Hricak¹,
Steven Larson¹,
Howard I. Scher² and
Hebert Alberto Vargas¹

¹Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

For correspondence or reprints, contact Andreas G. Wibmer (wibmera{at}mskcc.org).

View Full Text

Statistics from Altmetric.com

Cited By...

6 Citations
10 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients

Matteo Bauckneht, Francesco Bertagna, Maria Isabella Donegani, Rexhep Durmo, Alberto Miceli, Vincenzo De Biasi, Riccardo Laudicella, Giuseppe Fornarini, Alfredo Berruti, Sergio Baldari, Annibale Versari, Raffaele Giubbini, Gianmario Sambuceti, Silvia Morbelli, Domenico Albano

Prostate Cancer and Prostatic Diseases 2021 24 4
Salvage therapy for prostate cancer after radical prostatectomy

Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan

Nature Reviews Urology 2021 18 11
Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

Fadi Khreish, Kalle Ribbat, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Mathias Schreckenberger, Samer Ezziddin, Florian Rosar

Cancers 2021 13 16
Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [18F]-PSMA-1007 PET-CT

Elin Trägårdh, Olof Enqvist, Johannes Ulén, Jonas Jögi, Ulrika Bitzén, Fredrik Hedeer, Kristian Valind, Sabine Garpered, Erland Hvittfeldt, Pablo Borrelli, Lars Edenbrandt

Diagnostics 2022 12 9
Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes

Stephen R. Plymate, Cynthia Sprenger, Michael C. Haffner

Cell Reports Medicine 2022 3 2
Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Jiaxian Chen, Lin Qi, Yongxiang Tang, Guyu Tang, Yu Gan, Yi Cai

Frontiers in Cell and Developmental Biology 2022 10
Nuclear Oncology

Steven M. Larson

2022
Nuclear Oncology

Steven M. Larson

2022
Nuclear Oncology

Steven M. Larson

2022
The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad H. Stopsack, Christoph Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Z. Mazzu, Naga Vara Kishore Pillarsetty, Gwo-Shu Mary Lee, Howard I. Scher, Michael J. Morris, Tiffany Traina, Pedram Razavi, Wassim Abida, Jeremy C. Durack, Stephen B. Solomon, Matthew G. Vander Heiden, Lorelei A. Mucci, Andreas G. Wibmer, Nikolaus Schultz, Philip W. Kantoff

Clinical Cancer Research 2022 28 16

Article usage

Article usage: January 2021 to December 2022

	Abstract	Full	Pdf
Jan 2021	1741	0	53
Feb 2021	340	0	17
Mar 2021	218	0	17
Apr 2021	127	0	3
May 2021	169	0	6
Jun 2021	132	0	5
Jul 2021	374	23	57
Aug 2021	1163	65	109
Sep 2021	607	14	42
Oct 2021	522	19	28
Nov 2021	344	9	44
Dec 2021	348	7	22
Jan 2022	475	16	19
Feb 2022	63	336	22
Mar 2022	51	308	50
Apr 2022	41	196	26
May 2022	24	201	34
Jun 2022	36	303	23
Jul 2022	15	358	17
Aug 2022	18	293	32
Sep 2022	22	331	24
Oct 2022	14	188	28
Nov 2022	15	80	19
Dec 2022	22	391	17

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 8

August 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study